Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis C

Free Subscription 06.02.2023 1 Eur J Gastroenterol Hepatol 2 Hepatology 1 J Gastroenterol 1 J Hepatol 1 J Infect Dis 1 J Med Virol 2 PLoS One 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Eur J Gastroenterol Hepatol

1. LEE DU, Ponder R, Lee KJ, Yoo A, et al
   The nationwide trends in hospital admissions, deaths, and costs related to hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002498.
   PubMed         Abstract available
   
   

   
   Hepatology

2. LUO W, Zhang Y, Zhang T
   Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
   Hepatology. 2023;77:E26-E27.
   PubMed        
   
   
3. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
   Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
   Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
   PubMed         Abstract available
   
   

   
   J Gastroenterol

4. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
   Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
   J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
   PubMed         Abstract available
   
   

   
   J Hepatol

5. BURGER D, Aktas H, de Knegt R
   Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
   J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
   PubMed        
   
   

   
   J Infect Dis

6. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
   Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
   J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Med Virol

7. NOT A, Saludes V, Galvez M, Miralpeix A, et al
   Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
   J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
   PubMed         Abstract available
   
   

   
   PLoS One

8. AGHEMO A, Persico M, D'Ambrosio R, Andreoni M, et al
   Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
   PLoS One. 2023;18:e0280165.
   PubMed         Abstract available
   
   
9. ESSAYAGH F, Essayagh T, Essayagh M, Khouchoua M, et al
   Disease burden among migrants in Morocco in 2021: A cross‑sectional study.
   PLoS One. 2023;18:e0281129.
   PubMed         Abstract available
   
   

   
   Transplant Proc

10. BURGOS MM, Grande RG, Ortega SL, Leiva IS, et al
    Impact of HCV Treatment on Recurrence of Hepatocarcinoma After Liver Transplantation.
    Transplant Proc. 2023 Jan 25:S0041-1345(22)00884.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: